Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Endocrinol Invest ; 46(1): 89-101, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-35943723

RESUMO

PURPOSE: While SARS-CoV-2 infection appears not to be clinically evident in the testes, indirect inflammatory effects and fever may impair testicular function. To date, few long-term data of semen parameters impairment after recovery and comprehensive andrological evaluation of recovered patients has been published. The purpose of this study was to investigate whether SARS-CoV-2 infection affect male reproductive health. METHODS: Eighty patients were recruited three months after COVID-19 recovery. They performed physical examination, testicular ultrasound, semen analysis, sperm DNA integrity evaluation (TUNEL), anti-sperm antibodies (ASA) testing, sex hormone profile evaluation (Total testosterone, LH, FSH). In addition, all patients were administered International Index of Erectile Function questionnaire (IIEF-15). Sperm parameters were compared with two age-matched healthy pre-COVID-19 control groups of normozoospermic (CTR1) and primary infertile (CTR2) subjects. RESULTS: Median values of semen parameters from recovered SARS-CoV-2 subjects were within WHO 2010 fifth percentile. Mean percentage of sperm DNA fragmentation (%SDF) was 14.1 ± 7.0%. Gelatin Agglutination Test (GAT) was positive in 3.9% of blood serum samples, but no positive semen plasma sample was found. Only five subjects (6.2%) had total testosterone levels below the laboratory reference range. Mean bilateral testicular volume was 31.5 ± 9.6 ml. Erectile dysfunction was detected in 30% of subjects. CONCLUSION: Our data remark that COVID-19 does not seem to cause direct damage to the testicular function, while indirect damage appears to be transient. It is possible to counsel infertile couples to postpone the research of parenthood or ART procedures around three months after recovery from the infection.


Assuntos
COVID-19 , Infertilidade Masculina , Humanos , Masculino , Infertilidade Masculina/etiologia , Infertilidade Masculina/diagnóstico , Saúde Reprodutiva , COVID-19/complicações , SARS-CoV-2 , Sêmen , Testosterona
2.
Andrologia ; 48(3): 333-40, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26173956

RESUMO

The advent of modern treatments together with the improvement of the surgical techniques has significantly increased 5-year survival rates of young patients with cancer. Although the deleterious effects of chemotherapy and radiation are well documented, controversies exist about the effect of cancer itself on semen parameters before treatment. We collected data on 236 patients representative of different types of cancers reoffered at our institution for sperm cryopreservation with the aim to correlate the pre-freeze semen parameters with type of cancer, disease stage and with semen quality of 102 fertile and healthy men. The median baseline semen parameters of all our patients with cancer are placed above the 5th percentile of the World Health Organization reference value, but the type of cancer may impact the sperm parameters. In testicular tumours and in Hodgkin lymphoma, we show a semen concentration statistically lower than in the fertile population, while in patients with other cancers, there is no difference with the healthy men. We found no correlation between semen quality and disease stage. Eighty-six per cent of our patients do not have children at the time of semen cryopreservation, and the only established clinical option for preserving fertility of these men is cryopreservation of spermatozoa.


Assuntos
Neoplasias Hematológicas/patologia , Infertilidade Masculina/patologia , Motilidade dos Espermatozoides/fisiologia , Espermatozoides/patologia , Neoplasias Testiculares/patologia , Adolescente , Adulto , Idoso , Criopreservação , Humanos , Masculino , Pessoa de Meia-Idade , Análise do Sêmen , Preservação do Sêmen , Contagem de Espermatozoides , Adulto Jovem
3.
J Biol Regul Homeost Agents ; 29(4): 913-23, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26753656

RESUMO

The aim of the present study was to evaluate the effectiveness of the combined administration of myo-inositol and α-lipoic acid in polycystic ovary syndrome (PCOS) patients with normal body mass index (BMI), who had previously undergone intracytoplasmic sperm injection (ICSI) and received myo-inositol alone. Thirty-six of 65 normal-weight patients affected by PCOS who did not achieve pregnancy and one patient who had a spontaneous abortion were re-enrolled and given a cycle of treatment with myo-inositol and α-lipoic acid. For all female partners of the treated couples, the endocrine-metabolic and ultrasound parameters, ovarian volume, oocyte and embryo quality, and pregnancy rates were assessed before and after three months of treatment and compared with those of previous in vitro fertilization (IVF) cycle(s). After supplementation of myo-inositol with α-lipoic acid, insulin levels, BMI and ovarian volume were significantly reduced compared with myo-inositol alone. No differences were found in the fertilization and cleavage rate or in the mean number of transferred embryos between the two different treatments, whereas the number of grade 1 embryos was significantly increased, with a significant reduction in the number of grade 2 embryos treated with myo-inositol plus α-lipoic acid. Clinical pregnancy was not significantly different with a trend for a higher percentage for of myo-inositol and α-lipoic acid compared to the myo-inositol alone group. Our preliminary data suggest that the supplementation of myo-inositol and α-lipoic acid in PCOS patients undergoing an IVF cycle can help to improve their reproductive outcome and also their metabolic profiles, opening potential for their use in long-term prevention of PCOS.


Assuntos
Fertilização in vitro , Inositol/farmacologia , Oócitos/efeitos dos fármacos , Síndrome do Ovário Policístico/fisiopatologia , Ácido Tióctico/farmacologia , Adolescente , Adulto , Feminino , Humanos , Insulina/sangue , Projetos Piloto , Gravidez
4.
Transplant Proc ; 38(4): 1181-4, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16757300

RESUMO

The development of a small animal model for hepatitis C virus (HCV) infection is a critical issue for the development of novel anti-HCV drugs. To this aim, we have tried many different approaches for generating mice carrying humanized liver. Main efforts were focused on the transplantation of human hepatocytes into immunocompromised mice (SCID-/-, Bg-/-) carrying a genetic lethal liver disease (Alb-uPA). Survival of homozygotic animals should largely depend on early transplantation with healthy hepatocytes. In parallel to establishing a colony of Alb-uPA/SCID/Bg mice, we developed a microsurgical procedure for intrasplenic xenotransplantation of healthy hepatocytes in 1-week-old mice. So far, we generated several chimeras by xenotransplanting human hepatocytes in Alb-uPA+/+/SCID-/-/Bg-/- mice at 1 week after birth. In a first step, identification of successfully engrafted animals is possible by quantification of human serum albumin and human alpha 1 antitrypsin in mouse sera. Additional preliminary histomorphological analysis of liver sections from chimeric animals was also carried out. One of the mice was transiently infected with HCV, reaching viremia levels of approximately 10(5) genomes/mL. However, the efficiency of this system to generate chimeric mice is still very limited. We are currently exploring the use of more robust models of hepatic disease. Moreover, we have been also exploring novel strategies for the generation of chimeric mice by xenotransplanting human adult stem cells, instead of human hepatocytes, at preimmune stages of development.


Assuntos
Hepatite C/tratamento farmacológico , Hepatócitos/transplante , Animais , Anticorpos Monoclonais/uso terapêutico , Antivirais/uso terapêutico , Carcinoma Hepatocelular , Linhagem Celular Tumoral , Modelos Animais de Doenças , Humanos , Hepatopatias/cirurgia , Neoplasias Hepáticas , Camundongos , Camundongos SCID , Camundongos Transgênicos , Albumina Sérica/genética , Transplante Heterólogo , Ativador de Plasminogênio Tipo Uroquinase/genética
5.
Cytokine ; 12(9): 1395-9, 2000 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-10976001

RESUMO

H-IL-6 is a hybrid protein constructed to contain IL-6 and its soluble receptor linked by a flexible peptide chain. Here we show that H-IL-6 strongly enhances proliferation of human CD34(+)cells in serum-free liquid culture, and that the majority of the cells generated belong to the erythroid lineage, being positive for the marker Glycophorin A. Conversely, H-IL-6 does not increase the number of myeloid, CD13-positive cells. Comparable effects are observed on progenitors from cord blood and adult peripheral blood. Therefore, H-IL-6 triggers an erythroid-inducing signal in haematopoietic progenitor cells, independently from erythropoietin (EPO).


Assuntos
Antígenos CD34/biossíntese , Eritrócitos/citologia , Interleucina-6/metabolismo , Receptores de Interleucina-6/metabolismo , Antígenos CD13/metabolismo , Diferenciação Celular , Meios de Cultura Livres de Soro/metabolismo , Eritrócitos/metabolismo , Eritropoetina/farmacologia , Sangue Fetal/metabolismo , Citometria de Fluxo , Glicoforinas/biossíntese , Células-Tronco Hematopoéticas/metabolismo , Humanos , Leucócitos Mononucleares/metabolismo , Peptídeos/química , Proteínas Recombinantes de Fusão/metabolismo , Fator de Células-Tronco/farmacologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA